APONTIS PHARMA AG

APPH

Equity

ISIN DE000A3CMGM5 / Valor 111377632

Xetra (2024-09-18)

EUR 6.86-1.44%

APONTIS PHARMA AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

APONTIS PHARMA AG is a pharmaceutical company specializing in the development and commercialization of innovative medications.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Decline

APONTIS PHARMA AG reported a significant decline in total revenues for the fiscal year 2023, amounting to EUR 37.0 million, which represents a 34% decrease compared to the previous year. This decline was primarily attributed to the end of the Jalra/Icandra contract and supply issues affecting Atorimib.

EBITDA Impact

The company's EBITDA before restructuring costs was reported at EUR -13.3 million for FY 2023, a stark contrast to the previous year's positive EBITDA of EUR 5.6 million. This negative EBITDA was influenced by lower sales and one-time effects.

Single Pill Sales

Despite overall revenue challenges, APONTIS PHARMA AG saw strong growth in its Single Pill segment in Q4 2023. Products like Atorimib, Tonotec HCT, Tonotec Lipid, RosuASS 40, and LosAmlo showed significant sales increases, contributing positively to the company's performance in the last quarter of the year.

Restructuring Costs

APONTIS PHARMA AG incurred restructuring costs estimated between EUR 5.6 million and EUR 8 million in 2023. These costs were part of a broader effort to streamline operations and focus on high-value accounts and customers, aiming for profitability in 2024 and beyond.

Cash Flow and Liquidity

The company experienced a negative operating cash flow in 2023 due to losses and higher inventory levels. However, APONTIS PHARMA AG maintained a high equity ratio of 52.7% and sufficient cash reserves by the end of the year, supported by intragroup refinancing and a fixed-term deposit covering a loan until May 2024.

Summarized from source with an LLMView Source

Key figures

38.6%1Y

-71.8%3Y

%5Y

Performance

45.3%1Y

58.3%3Y

56.8%5Y

Volatility